A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/557 (2006.01) A61K 9/00 (2006.01) A61K 31/5575 (2006.01) A61P 9/12 (2006.01)
Patent
CA 2280089
An improved ophthalmic composition, including prostaglandin active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achieved by utilizing the disclosed compositions which include a prostaglandin active agent (e.g., isopropyl unoprostone, a metabolite of an F-series prostaglandin), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents.
L'invention concerne une composition ophtalmique améliorée. Cette composition comprend des substances actives de la prostaglandine et est particulièrement utile pour abaisser la pression intraoculaire associée au glaucome. Cette composition présente des améliorations de l'efficacité de la réduction de la pression intraoculaire, de l'efficacité des agents de conservation et des concentrations d'additifs réduites car elle comporte une substance active de la prostaglandine (par exemple, de l'isopropyl unoprostone, un métabolite d'une prostaglandine de la série F) en association avec des tensio-actifs non ioniques sélectionnés, des conservateurs et des agents d'ajustement de la tonicité non ioniques.
Peacock Regina Flinn
Reed Kenneth Warren
Sou Mary
Yen Shau-Fong
Fetherstonhaugh & Co.
Novartis Ag
LandOfFree
Compositions and methods for reducing ocular hypertension does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for reducing ocular hypertension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for reducing ocular hypertension will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2014913